newsfilter
← Latest News
GlobeNewswire·

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with